Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9307188 | Actas Urológicas Españolas | 2005 | 7 Pages |
Abstract
No high-quality clinical evidence can be established currently on the utility of HIFU as treatment of prostatic cancer. An important fact to stress is the capacity of therapy to produce tumour necrosis both as first-step treatment and as salvage therapy. No conclusions can be drawn in the long-term due to the paucity of controlled and randomized trials with adequate follow-up to establish benefits in terms of global survival and quality of life (balance adversal effects/benefits), lack of comparisons with standard options as long as different definitions of free-survival disease.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
E. Lledó GarcÃa, J. Jara Rascón, D. Subirá RÃos, F. Herranz Amo, J.I. MartÃnez-Salamanca, C. Hernández Fernández,